GENSCRIPT BIO (01548.HK): Partners with Lilly's TuneLab Platform to Provide Wet-lab Services
- The announcement was published at the request of The Stock Exchange of Hong Kong Limited after the Board noted an increase in the price and trading volume of the Company's shares on that day.
- Lilly is a multinational pharmaceutical company listed on the New York Stock Exchange with ticker LLY.
- The Board confirmed that, save as disclosed, it is not aware of any reason for the fluctuations in the price or trading volume of the shares, and that the agreement does not constitute inside information under Part XIVA of the Securities and Futures Ordinance.
NewTimeSpace News: On 17 September 2026, Genscript Biotech Corporation (stock code: 01548) published an announcement under Rule 13.10 of the Listing Rules at the request of The Stock Exchange of Hong Kong Limited, stating that the Board noted an increase in the price and trading volume of the Company's shares on that day. The Board also provided an update on the Group's recent business developments, disclosing that the Company has entered into an agreement to collaborate with Lilly TuneLab™(TuneLab), an AI-driven (AI/machine learning) drug discovery collaboration platform founded by Eli Lilly and Company (Lilly), a multinational pharmaceutical company listed on the New York Stock Exchange (ticker: LLY).
Under the agreement, the Group will provide wet-lab services to TuneLab participating enterprises at preferential rates to help generate experimental data and translate AI predictions into biological evidence data. The Board considers that the agreement will further expand the Group's presence in the fast-growing AI-driven drug discovery ecosystem, consistent with its strategic direction of supporting biopharmaceutical innovation through integrated research and development solutions.
The Board further confirmed that the agreement does not constitute inside information of the Company within the meaning of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Having made reasonable enquiries in the circumstances, the Board confirmed that, as at the date of the announcement and save as disclosed therein, it is not aware of any reason for the fluctuations in the price or trading volume of the shares, nor of any inside information required to be disclosed under Part XIVA of the Securities and Futures Ordinance, and reminded shareholders and potential investors to exercise caution when dealing in the Company's securities.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- GLOBAL NEW MAT (06616.HK): To Issue RMB 1.3 Billion Convertible Bonds, Concurrently Repurchasing HKD 990 Million of Existing Bonds
- GALAXIS TECH (02729.HK): Interim Revenue Up 45.1% to RMB 504.9 Million, Loss Narrows to RMB 73.3 Million
- FU SHOU YUAN (01448.HK): Gong Hailin Makes Unconditional Partial Offer at HK$ 0.1 per Share for Up to 115 Million Shares
- TIANJIN DEV (00882.HK): Interim Profit Attributable to Shareholders HK$ 325.2 Million, Interim Dividend HK 5.18 Cents
- VESON HLDG (01399.HK): Interim Turnover Up 16.1%, Turns to Profit of RMB 20.3 Million
